Eight Dragonfly-developed drugs are in clinical trials now, with our lead drug in Phase 2. Four more Dragonfly-developed drugs are expected in the clinic by the end of 2024.
DRAGONFLY invents novel therapies that harness the body’s immune system for vastly improved Patient Outcomes.
We build drugs in autoimmune disease, oncology, fibrosis, neuro-inflammation, and beyond.
In collaboration with AbbVie, BMS, Gilead and Merck, our novel TriNKET® and CYTOKINE platforms have generated 11 Drug Candidates that have been handed off to partners.
Activating the Immune
System to Fight Disease
The company announces the first patient dosed in a Phase 1/1b clinical trial evaluating its novel IL-2 cytokine, DF6215, the seventh Dragonfly-developed drug to enter into clinical trials.
DRAGONFLY is a distinctively effective pharma partner.
Dragonfly rapidly develops drugs with our pharma partners in expanding fields from autoimmune disease and oncology, to neuro-inflammation, neuromuscular disease, virology, and beyond.
Two Proprietary Platforms
DRAGONFLY is a clinical-stage biotech that has developed a deep portfolio of drugs built on two unique platforms: first-in-class tri-specific immune engagers (“TriNKET®s”)
and best-in-class CYTOKINEs – each with lead
drugs in the clinic with encouraging results.
Pipeline for Patients
In addition to a set of advanced programs in the clinic or handed off to our pharma partners, DRAGONFLY is developing 30+ TriNKETs® and multiple CYTOKINES across a broad range of fields, including autoimmune and inflammatory diseases, fibrosis, neurology, infectious disease, and oncology.